Abstract 726P
Background
Adrenocortical carcinoma (ACC) is a rare aggressive endocrine cancer with heterogeneous behaviour. Disease surveillance relies on frequent imaging, which comes with significant radiation exposure. We investigated the role of circulating cell-free DNA (ccfDNA)-related biomarkers (BM) for prognostication and monitoring of ACC.
Methods
We studied 33 patients with primary ACC and 23 healthy subjects (HS) as controls. ccfDNA was extracted by commercial kits from pre-surgical and serial EDTA plasma samples and quantified by fluorimeter (BM1). All ccfDNA samples passed the quality check showing a desired fragment length of 150-200 bp. Primary tumour DNA was isolated from paraffin-embedded tissue for 25/33 patients. Next-generation sequencing was performed using a customised panel of 30 ACC-specific genes (Cell3TM Target Nonacus). Leucocyte DNA was sequenced to discriminate germline from somatic variants (BM2). BM1 and BM2 were merged into a combined ccfDNA-BM score to be correlated with clinical outcome.
Results
ccfDNA concentrations were higher in ACC than HS (median 0.40 vs 0.05 ng/μl, P<0.001) and correlated with tumour stage and ki67 index (R=0.48 and 0.55, respectively). 94% of ACC were positive for BM1 (cut off 0.146 ng/μl, median HS+2SD) and 45.5% for BM2 (at least one somatic mutation in ccfDNA, variant allele frequency 1.0-30.5%). Mutational status at ccfDNA matched with tumour DNA in 60% of cases (additional variants in 16% and missed variants in 12%). ccfDNA-BM score (0-1=negative, 2-3=positive) was strongly associated with progression-free and overall survival (P=0.0004, HR=8.68, 95%CI=2.88-26.5, and P=0.003, HR=3.35, 95%CI=1.34-8.37, respectively). Among 13 patients followed up for at least 3 months (range 1-6), 10 tumour-free at last imaging and 1/3 with early relapse had negative ccfDNA-BM score (100% vs 33%). In two recurrent cases, somatic mutations in ACC-specific genes remained detectable during monitoring.
Conclusions
ccfDNA-related BMs are frequently detected in patients with ACC, representing a promising non-invasive tool to predict early disease recurrence and complement imaging for monitoring. Our findings will be validated in a larger cohort of ACCs with long-term follow up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Deutsche Krebshilfe Stifftung (Project Grant 70113526), patient association AMEND (Research Fund).
Disclosure
C.L. Ronchi: Financial Interests, Personal, Research Grant: HRA Pharma. A. Prete: Financial Interests, Personal, Research Grant: NIHR. All other authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11